Maria is responsible for the innovative Cancer Research UK (CRUK) – AstraZeneca (AZ) Antibody Alliance Laboratory. She manages a multidisciplinary team of 14 scientists from both CRUK and AstraZeneca at this CRUK-funded facility.

The laboratory utilises AstraZeneca’s core Antibody Discovery and Protein Engineering technologies and capabilities to discover candidate drugs for future evaluation in the treatment of cancer. This innovative Alliance has access to the CRUK oncology Principal Investigator (PI) network, which represents over 4000 researchers throughout the UK. Maria leads the Alliance team to work with selected PIs on a current portfolio of 8 projects. In 2018, the Alliance Lab was independently reviewed and described as having ‘world class’ antibody discovery capabilities.

Maria is also an industry recognised expert and leader in the field of ribosome display and protein engineering. She joined Cambridge Antibody Technology in 2000 and established herself as an externally recognised scientific expert in ribosome display.

As a project leader, her biggest success to date has been leading the R&D phase of MEDI1814 – an antibody therapeutic being explored for the potential treatment of Alzheimer’s Disease which is now in Phase 1 clinical trials.

 

I am really excited to be able to play a significant role in the Alliance Laboratory with Cancer Research UK. Collaborating with CRUK and accessing oncology knowledge from the scientists within those thousands of groups is going to help us to find some really novel targets so we can generate innovative therapeutics with the aim of helping cancer patients.

Maria Groves Associate Director, Head of the CRUK AZ Antibody Alliance Laboratory

CURRENT ROLE

Head of the Cancer Research UK AZ Antibody Alliance Laboratory

MEDI1814 FOR ALZHEIMER’S DISEASE

Candidate Drug nomination in 2012

CONFERENCE PRESENTATION

IBC Antibody Engineering Conference Presenter 2014

  Featured publications

Antibodies binding the head domain of P2X4 inhibit channel function and reverse neuropathic pain

Williams WA, Linley JE, Jones CA et al. 2019. PAIN: 160 (9): 1989–2003

Anti‐PrPC antibody rescues cognition and synapses in transgenic alzheimer mice

Cox TO, Gunther EC, Brody AH et al. 2019. Anals of Clinical and Translational Neurology: 6(3): , 554-574

Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope “tags”

Percival-Alwyn JL, England E, Kemp B, et al. mAbs, 2015. 7(1): p. 129-137.

Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity

Groves MA, Amanuel L, Campbell JI, et al. mAbs, 2013. vol 6 (1): p. 61-68.

An efficient and easily accessible eukaryotic ribosome display technology.

Douthwaite JA, Groves MA and Dufner P. Protein Eng. Des Sel, 2006. 19(2): p. 85-90

Affinity Maturation of Phage Display Antibody Populations Using Ribosome Display

Groves, M, Lane S, Douthwaite J et al. J Immunol. Methods, 2006. 313(1-2): p. 129-39.

From rodent reagents to human therapeutics using antibody guided selection

Osbourn, J, Groves M, and Vaughan T. Methods, 2005. 36(1): p. 61-8.